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Calcineurin is a widely expressed and highly conserved Ser/Thr phosphatase. Calcineurin is inhibited
by the immunosuppressant drug cyclosporine A (CsA) or tacrolimus (FK506). The critical role of CsA/
FK506 as an immunosuppressant following transplantation surgery provides a strong incentive to under-
stand the phosphatase calcineurin. Here we uncover a novel regulatory pathway for cyclic AMP (cAMP)
signaling by the phosphatase calcineurin which is also evolutionarily conserved in Caenorhabditis elegans.
We found that calcineurin binds directly to and inhibits the proteosomal degradation of cAMP-hydrolyz-
ing phosphodiesterase 4D (PDE4D). We show that ubiquitin conjugation and proteosomal degradation of
PDE4D are controlled by a cullin 1-containing E3 ubiquitin ligase complex upon dual phosphorylation by
casein kinase 1 (CK1) and glycogen synthase kinase 3 (GSK3) in a phosphodegron motif. Our findings
identify a novel signaling process governing G-protein-coupled cAMP signal transduction—opposing
actions of the phosphatase calcineurin and the CK1/GSK3 protein kinases on the phosphodegron-
dependent degradation of PDE4D. This novel signaling system also provides unique functional insights
into the complications elicited by CsA in transplant patients.
Calcineurin (also known as protein phosphatase 2B) was
first identified as a calcium/calmodulin-binding protein in brain
extracts (40, 57). Further analysis demonstrated that cal-
cineurin is a widely expressed and highly conserved phos-
phatase (5, 19, 21, 25, 53). Calcineurin is inhibited by the
immunosuppressant drug cyclosporine A (CsA) or tacrolimus
(FK506) (17, 24, 43). CsA (or FK506) forms complexes with
cyclophilins (or FK506-binding proteins) and inhibits cal-
cineurin. The critical role of CsA and FK506 as immunosup-
pressants following transplantation surgery (16, 45, 46, 48)
provides a strong incentive to understand the phosphatase
calcineurin.
At the molecular level, calcineurin contributes to immune
regulation by inhibiting the transcription factor NFAT (nu-
clear factor of activated T cells). The transcription factor
NFAT family was first identified as an important regulator of
interleukin-2 (IL-2) gene expression (23). NFAT is located in
the cytosol of resting cells (20, 30). Increased intracellular
calcium activates the phosphatase calcineurin, which binds to a
calcineurin docking motif (PXIXIT) (4, 6, 15) and dephosphor-
ylates NFAT. Administration of CsA to transplant patients
inhibits calcineurin and blocks the nuclear translocation of
NFAT. Hence, NFAT remains in the cytosol and the expres-
sion of cytokine genes such as that for IL-2 is reduced. Since
IL-2 is a critical mitogen of T cells, a reduced level of IL-2
abrogates T-cell differentiation and minimizes the incidence of
host-versus-graft reactions in transplant patients.
Despite the tremendous advantages of CsA and FK506 in-
hibition of calcineurin after transplantation surgery, prolonged
treatment with CsA or FK506 produces many side effects,
including diabetes mellitus, hyperlipidemia, nephrotoxicity,
neuronal damage, and cardiovascular disease (3, 26, 38, 48).
The current model indicates that calcineurin-NFAT signaling
regulates the growth and differentiation of beta cells in the
pancreatic islets (27, 28). In the presence of CsA, changes in
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insulin signaling could account for the complications found in
transplant patients.
Here we uncover a novel signaling system which centers on
calcineurin controlling ubiquitin conjugation and proteosomal
degradation of cyclic AMP (cAMP)-hydrolyzing phosphodies-
terase 4D (PDE4D). Degradation of PDE4D is channeled
through a cullin 1 (Cul1)-containing E3 ubiquitin ligase com-
plex and is dependent on dual phosphorylation carried out by
casein kinase 1 (CK1) and glycogen synthase kinase 3
(GSK3). Integration of calcineurin, CK1, GSK3, and Cul1 is
also evolutionarily conserved in Caenorhabditis elegans. This
new signaling system expands the repertoire of calcineurin
substrates and indicates that calcineurin impinges on phos-
phodependent protein degradation. We propose that this
novel calcineurin signaling system provides new insights into
alternative therapeutic targets for a range of adverse patho-
logical complications elicited by CsA in transplant patients.
MATERIALS AND METHODS
Mice. Animal experiments were performed in accordance with the guidelines
of the Albert Einstein College of Medicine Institute of Animal Studies. CnA/
mice were generated as described previously, by the insertion of a neomycin
resistance gene to disrupt exon 2 (12). CnA/ mice were backcrossed with
C57BL/6 mice at least 10 times before use. Backcrossed CnA/ mice were also
used for the isolation of mouse embryonic fibroblasts (MEFs).
Worm strains. C. elegans strains were maintained under standard culture
conditions on NGM agar plates with Escherichia coli OP50 as a food source (10).
Wild-type animals were of Bristol strain N2 (a kind gift from Ji Ying Sze).
Loss-of-function calcineurin tax-6(p675lf) (41) and PDE-4 pde-4(ok1290) mu-
tants were a kind gift from Ji Ying Sze or obtained from the Caenorhabditis
Genetics Center.
Reagents. Mouse CnA was amplified by PCR from mouse mammary gland
cDNA and hemagglutinin (HA) tagged using primers 5-AGGAATTCGCCAC
CATGTACCCATACGATGTTCCAGATTA CGCTGCCGCCCCGGAGCCG
GCC-3 and 5-CTCGAGTCACTGGGCACTATGGTT-3. The PCR product
was subcloned into the vector pCDNA3 using the EcoRI and XhoI sites. C.
elegans PDE4 was amplified by PCR from plasmid KM#203 (a kind gift from
Ken Miller) (13) and FLAG tagged using primers 5-GATCGGATCCCGGCA
GCCAACATGCCACGAAGACGCGGCTCGTCGTCGTCGTCGTCG-3 and
5-GATCGAATTCTCATTTGTCATCATCGTCCTTATAGTCTTTGTGCTC
GTCATCTTCTGTTACAGT-3. The PCR product was subcloned into the vec-
tor pCDNA3 using the BamHI and EcoRI sites. Expression vectors for VSV-
G-tagged PDE4D3, VSV-G-tagged PDE4D5, FLAG-tagged GSK3, HA-tagged
CK1, FLAG-tagged dominant negative Cul1, HA-tagged ubiquitin, and C.
elegans PDE4 (KM#203) have been described previously (13, 37, 44, 59, 60, 63).
Point mutations were generated by the QuikChange protocol and sequenced.
Recombinant PDE4D was expressed using the vector pGEX-5X1 by cloning into
the BamHI and XhoI sites. Antibodies for PDE4D (sc25814 and sc25097), the
VSV-G tag (sc66180), the HA tag (sc7392), the FLAG tag (F3185), calcineurin
A (sc6124 and sc17808), and calcineurin B (sc6119) were obtained from Santa
Cruz or Sigma. Polyclonal antibodies against phospho-Thr were obtained from
Invitrogen (71-8200). Tubulin antibody (clone E7) was obtained from the mono-
clonal antibody facility at the University of Iowa. Polyclonal antibodies against
PDE4D and C. elegans PDE4 were described previously (9, 13). Antibodies to
phospho-Ser616 were generated by using the synthetic phosphopeptide Cys-Glu-
Ser-Asp-Thr-Glu-Lys-Asp-Ser(P)-Gly-Ser-Gln-Val-Glu-Glu-Asp and conju-
gated to keyhole limpet hemocyanin. The phosphospecific antibody was affinity
purified from rabbit serum as described previously (62). The PDE inhibitors
IBMX and rolipram, the calcium ionophore ionomycin (Ion), the calcineurin
inhibitor CsA, the GSK3 inhibitor lithium chloride (LiCl), the CK1 inhibitor
D4476, the CK2 inhibitor 2-dimethylamino-4,5,6,7-tetrabromo-1H-benzimida-
zole (DMAT), and the proteosome inhibitor MG132 were obtained from Cal-
biochem, Sigma, and/or Fisher Thermo Scientific.
Cell culture. MEFs were prepared from E13.5/14.5 embryos after trypsin
digestion as described previously (61). MEFs and COS7 cells were cultured in
Dulbecco modified Eagle medium supplemented with 10% fetal calf serum, 2
mM L-glutamine, penicillin (100 U/ml), and streptomycin (100 g/ml). COS7
cells were transfected using Lipofectamine (Invitrogen) according to the manu-
facturer’s protocol. Cells were harvested in Triton lysis buffer (20 mM Tris [pH
7.4], 134 mM NaCl, 2 mM EDTA, 25 mM -glycerophosphate, 2 mM NaPPi,
10% glycerol, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride, 1 mM
benzamidine, 10 g/ml leupeptin).
Semiquantitative RT-PCR. Total RNA was isolated from MEFs using TRIzol
reagent (Invitrogen). Five micrograms of RNA was reverse transcribed into
cDNA using superscript II reverse transcriptase (Invitrogen). Semiquantitative
reverse transcription (RT)-PCR was performed for each sample in triplicate with
two different concentrations of cDNA to establish linear amplification. Twenty
PCR cycles were amplified. The primers used for RT-PCR were as follows: for
PDE4A, 5-CCTGCCTGACAAGTTCCAAT-3 and 5-AGCAGAGATGACG
GCAGAAT-3; for PDE4B, 5-ATCACCTTGCTGTGGGATTC-3 and 5-AA
CCAACCTGGGATTTTTCC-3; for PDE4D, 5-GTCCCATGTGTGACAAG
CAC-3 and 5-CAAGTTTCAGGCTGGCTTTC-3; for PDE7A, 5-TGCTGC
AGACGTTACTCAGG-3 and 5-AGCACATTTCAAGGCCATCT-3.
Half-life determination. The plasmid for VSV-G-tagged PDE4D3 expression
was transfected into COS7 cells. Cells were treated with cycloheximide (CHX;
0.5 mM) in the presence or absence of CsA (5 M) for 0, 1, 2, or 4 h before
harvest. The effect of the transcriptional inhibitor actinomycin D (ActD; 0.5
g/ml) was also examined.
Protein kinase assays. Glutathione S-transferase (GST) recombinant protein
(2 g) encompassing either the NH2 or COOH terminus of the catalytic core of
PDE4D was incubated with purified GSK3 or CK1 (5 U) in the presence of
[-32P]ATP for 30 min. Phosphorylation of PDE4D was examined by sodium
dodecyl sulfate-gel electrophoresis and autoradiography.
Binding assays. The plasmid for VSV-G-tagged PDE4D3 expression was
cotransfected with HA-tagged CnA into COS7 cells. Cell extracts prepared
using Triton lysis buffer were incubated with protein G-agarose and HA antibody
to immunoprecipitate CnA in coimmunoprecipitation assays. Binding assays
were also performed by using GST or GST-PDE4D recombinant protein and
purified calcineurin. After three washes with Triton lysis buffer, the bound
proteins were detected by immunoblot analysis.
Statistical analysis. The data shown are means  standard errors of the
means. The Student t test was performed, and P values of 0.05 were considered
to be significant.
RESULTS
Posttranscriptional regulation of PDE4D expression by cal-
cineurin. We initially set out to determine whether calcineurin
contributes to the regulation of cAMP-hydrolyzing PDE4D,
given that targeted disruption of calcineurin led to metabolic
complications with dysregulation in the -adrenergic G-pro-
tein-coupled receptor (GPCR)/cAMP signaling pathway (data
available on request). Among the 11 PDE families, PDE4 was
chosen because of its widespread expression in different cells
and tissues (18, 32). Indeed, PDE4 accounts for the bulk of
the total cAMP-hydrolyzing PDE activity in primary MEFs
(11). Furthermore, PDE4 can be regulated upon phosphor-
ylation by protein kinase A (PKA) and/or ERK (29, 55),
which are downstream effectors of the -adrenergic recep-
tor signaling pathway.
Unexpectedly, we found that the levels of PDE4D expres-
sion were potentiated upon coexpression with CnA (Fig. 1).
Increased protein expression was found in at least two different
members of the PDE4D family, including PDE4D3 and
PDE4D5 (Fig. 1A). CnA, however, affected neither the level
of expression of exogenous -arrestin 1 (Arr-1) nor the levels
of expression of endogenous tubulin and insulin growth factor
receptor. These data indicate that CnA regulates PDE4D3
and PDE4D5 expression.
We further ascertained calcineurin regulation of PDE4D
expression by using the calcium ionophore ionomycin to acti-
vate calcineurin and the calcineurin inhibitor CsA (Fig. 1B and
C). In the presence of ionomycin, the expression levels of
endogenous PDE4D in MEFs were potentiated (Fig. 1B). The
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expression levels of endogenous PDE4D were also potentiated
by serum stimulation, which induced a Ca2 influx (Fig. 1B).
Administration of CsA, however, reduced PDE4D3 expression
(Fig. 1C). Notably, CsA abrogated the potentiation of
PDE4D3 expression elicited by ionomycin (Fig. 1C). These
data confirm that calcineurin regulates PDE4D expression.
To investigate the role of calcineurin in PDE4D protein
expression, we determined the half-lives of PDE4D3 in the
presence and absence of CsA (Fig. 1D). In the presence of the
translational inhibitor CHX, we noted that the half-life of
PDE4D3 was 	4 h (Fig. 1D). Administration of CsA reduced
the half-life of PDE4D3 to 	1 h (Fig. 1D). These data indicate
that calcineurin regulates the degradation of the PDE4D3 pro-
tein.
Given the prominent role of calcineurin in transcription
regulation (20, 30), we asked whether the role of calcineurin in
PDE4D3 potentiation was also transcription dependent (Fig.
1E). Unlike the effect of a translation inhibitor, administration
of CsA in the presence of the transcription inhibitor ActD did
not further reduce the half-life of PDE4D3 (Fig. 1E). These
data indicate that calcineurin regulates the posttranscriptional
degradation of the PDE4D3 protein.
Ubiquitin-mediated degradation of PDE4D via a phospho-
degron motif. Ubiquitin conjugation and subsequent proteo-
some-mediated degradation play a critical role in protein turn-
over (49, 50). We have identified a potential phosphodegron
(DSGSQVEED623) located in the COOH-terminal conserved
catalytic core of PDE4D (Fig. 2A). In general, a phosphode-
gron (e.g., DpSGX2-4pS) promotes the polyubiquitin-mediated
degradation of phosphoproteins via the Skp1-Cul-F box recep-
tor (SCF) E3 ubiquitin ligase complex (34, 36). Phosphodepen-
dent degradation of PDE4D has also been implicated in a
recent genome-wide identification of Cul1 substrates (65, 66).
The location of the phosphodegron in the COOH-terminal
conserved catalytic core further suggests that all PDE4D iso-
forms are regulated similarly.
Here we show that PDE4D degradation can be channeled
through the polyubiquitin-dependent proteosome pathway
(Fig. 2B). Indeed, in the presence of the proteosome inhibitor
MG132, degradation was reduced while ubiquitin conjugation
of PDE4D was increased (Fig. 2B). Notably, expression of
dominant negative Cul1 (
Cul1), which blocks recruitment
and subsequent protein degradation mediated by the SCF E3
ubiquitin ligase complex, also reduced PDE4D degradation
FIG. 1. Posttranscriptional regulation of PDE4D expression by calcineurin. (A) Extracts prepared from COS7 cells transiently transfected with
PDE4D3, PDE4D5, or Arr-1 were examined by immunoblot analysis. The effect of coexpression of CnA is also shown. Expression of
endogenous IGF-1 receptor (IGF-1) and tubulin is shown as a control. (B) Expression of endogenous PDE4D in MEFs was detected by
immunoprecipitation (IP) using rabbit (Rb) polyclonal PDE4D antibody (sc25814) and subsequent immunoblot analysis (IB) using goat (Gt)
polyclonal PDE4D antibody (9). The effect of the calcium ionophore ionomycin and mitogenic stimuli (20% fetal calf serum) is also shown.
(C) Extracts prepared from COS7 cells transiently transfected with PDE4D3 were treated with the calcium ionophore Ion (2 M) and/or the
calcineurin inhibitor CsA (5 M). Expression of PDE4D3 was determined by immunoblot analysis. (D) COS7 cells were transiently transfected
with PDE4D3. The half-life of PDE4D3 was determined in the presence CHX (0.5 mM). The effect of CsA (5 M) is also shown. Expression of
tubulin was used as a control. (E) COS7 cells were transiently transfected with PDE4D3. The half-life of PDE4D3 was determined in the presence
of CsA (5 M). The effect of the transcription inhibitor ActD (0.5 g/ml) or the translational inhibitor CHX (0.5 mM) was examined. *, P  0.05;
#, P  0.005.
VOL. 30, 2010 CALCINEURIN REGULATES PDE4D DEGRADATION 4381
(Fig. 2C). These data indicate that the degradation of PDE4D
is mediated by a Cul1-containing SCF E3 ubiquitin ligase com-
plex.
Next, we determined the role of the phosphodegron in
PDE4D degradation (Fig. 2D to F). Phosphodegron-defective
PDE4D (Ala616, Ala618, Ala616,618, or Ala621-623) exhibited in-
creased expression compared to the wild type (Fig. 2D to F). In
the presence of CHX, the half-life of phosphodegron-defective
PDE4D was potentiated (Fig. 2G). Expression of 
Cul1 re-
duced PDE4D degradation (Fig. 2D). The effect of 
Cul1 on
PDE4D degradation, however, was abrogated in phosphode-
gron-defective PDE4D (Fig. 2D). These data indicate that
degradation of PDE4D by the SCF E3 ubiquitin ligase complex
is phosphodegron dependent.
Reduced degradation of phosphodegron-defective PDE4D
in the presence of the proteosome inhibitor MG132 was also
confirmed. In the presence of MG132, the expression and
ubiquitin conjugation of PDE4D were potentiated (Fig. 2E
and F). Phosphodegron-defective PDE4D, however, exhibited
reduced ubiquitin conjugation despite potentiated expression
(Fig. 2E and F). Together, these data indicate that the phos-
phodegron is required for ubiquitin-mediated degradation of
β
κ α
κ
∆
∆
∆
∆
FIG. 2. Ubiquitin-mediated degradation of PDE4D via a phosphodegron motif. (A) Schematic illustration of the location of the DSGSQVEED
phosphodegron in PDE4D3. Sequences of known phosphodegrons are also shown. Conserved amino acid residues and phosphorylated Ser are
highlighted and underlined, respectively. A phosphodegron-like motif (DSGSQVEED) and potential phosphorylation sites (Ser616 and Ser618) in
PDE4D3 are also shown. (B) COS7 cells were transiently transfected with PDE4D3. Ubiquitin conjugation of PDE4D3 was determined by
coimmunoprecipitation assays. The presence of ubiquitin in PDE4D3 immunoprecipitates (IP) was analyzed by immunoblot (IB) analysis. The
effect of the proteosome inhibitor MG132 (10 M) is also shown. (C) COS7 cells were transiently transfected with PDE4D3. The expression levels
of PDE4D3 in the presence and absence of dominant negative Cul1 (
Cul1) were determined by immunoblot analysis. (D) COS7 cells were
transiently transfected with wild-type or phosphodegron-mutated (Ala616, Ala618, Ala616,618, or Ala621,622,623) PDE4D3. The expression levels of
wild-type and phosphodegron-mutated PDE4D3 were determined in the presence and absence of 
Cul1. (E) COS7 cells were transiently
transfected with wild-type or phosphodegron-mutated (Ala616, Ala618, Ala616,618, or Ala621,622,623) PDE4D3. The expression levels of wild-type and
phosphodegron-mutated PDE4D3 were determined in the presence and absence of the proteosome inhibitor MG132 (10 M). (F) COS7 cells
were transiently transfected with wild-type or phosphodegron-mutated (Ala616, Ala618, Ala616,618, or Ala621,622,623) PDE4D3. Ubiquitin conjugation
of wild-type and phosphorylation-defective PDE4D3 was determined by coimmunoprecipitation assays. The presence of ubiquitin in PDE4D3
immunoprecipitates was analyzed by immunoblot analysis. The effect of the proteosome inhibitor MG132 (10 M) is also shown. (G) COS7 cells
were transiently transfected with wild-type or phosphodegron-mutated (Ala616,618) PDE4D3. The half-lives of wild-type and phosphorylation-
defective PDE4D3 were determined in the presence of CHX (0.5 mM) and CsA (5 M). *, P  0.05; #, P  0.005.
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PDE4D via a Cul1-containing SCF E3 ubiquitin ligase com-
plex.
Calcineurin regulation of PDE4D degradation is phospho-
degron dependent. Given that calcineurin potentiates PDE4D
expression (Fig. 1), we therefore asked whether calcineurin
regulation is also phosphodegron dependent (Fig. 3). Expres-
sion of calcineurin reduced PDE4D degradation (Fig. 3). The
effect of calcineurin on PDE4D degradation, however, was
abrogated in phosphodegron-defective PDE4D (Fig. 3). Re-
duced degradation of phosphodegron-defective PDE4D in the
presence of pharmacological agents that modulate endogenous
calcineurin activity was also confirmed (data available on re-
quest). Administration of the calcium ionophore ionomycin
reduced, while the calcineurin inhibitor CsA potentiated,
PDE4D degradation (data available on request). The effect of
ionomycin and CsA on PDE4D degradation, however, was
abrogated in phosphodegron-defective PDE4D (data available
on request). These data illuminate the role of calcineurin, via
the phosphodegron, on PDE4D protein degradation.
Mapping of functional PxIxIT-like calcineurin docking mo-
tifs in PDE4D. Previous studies established that calcineurin
interacts with its substrates via a PXIXIT docking motifs (4, 6,
15). For example, conserved PXIXIT docking motifs are found
in all four calcineurin-regulated NFAT family members (Fig.
4A), which play an important role in cytokine gene transcrip-
tion and contribute significantly to the success of transplant
surgery (30). Replacement of the PXIXIT motif with Ala at-
tenuates the dephosphorylation of NFAT by calcineurin (4, 6,
15). In addition, the PXIXIT-containing peptide domain acts
in a dominant negative fashion and interferes with calcineurin
interaction and subsequent dephosphorylation (4, 6, 15),
thereby inhibiting NFAT-mediated cytokine gene transcrip-
tion. Similar PXIXIT motifs are found in calcineurin substrates
in yeast (Fig. 4A) (21), indicating an evolutionarily conserved
FIG. 3. Calcineurin regulation of PDE4D degradation is phospho-
degron dependent. Wild-type or phosphodegron-mutated (Ala616,
Ala618, Ala616,618, or Ala621,622,623) PDE4D3 was coexpressed with
CnA in COS7 cells. The expression levels of PDE4D3 and CnA
were determined by immunoblot analysis. The expression level of
tubulin was used as a control.
FIG. 4. Mapping of functional PXIXIT-like calcineurin docking motifs in PDE4D. (A) Schematic illustration of the locations of the two
functional PXIXIT-like motifs (PLNLYR496 and PEACVI666) in the catalytic core of PDE4D3. The location of the DSGSQVEED phosphodegron
in PDE4D3 is also indicated. A sequence comparison of known calcineurin docking PXIXIT motifs found in human NFAT and yeast proteins is
shown. Potential PXIXIT-like motifs in PDE4D3 and an optimized PXIXIT motif (PVIVIT) are also shown. Functional PXIXIT-like motifs in
PDE4D3 are highlighted. (B) Wild-type and PXIXIT-mutated PDE4D3 were transiently transfected into COS7 cells. The expression levels of
wild-type and PXIXIT-mutated PDE4D3 were determined in the presence and absence of Ion (2 M) and/or CsA (5 M). The expression of
tubulin was used as a control. Replacements of critical amino acid residues with Ala in potential PXIXIT-like motifs of PDE4D3 are underlined.
Functional PXIXIT-like motifs in PDE4D3 are highlighted.
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enzyme-substrate mechanism mediated by calcineurin docking
via the PXIXIT motif.
We have identified several putative PXIXIT-like calcineurin
docking motifs in the COOH-terminal conserved catalytic core
of PDE4D (Fig. 4A). We surmised that some of these motifs
are functional and are critical in mediating the effect of cal-
cineurin on PDE4D degradation. Thus, we performed site-
direct mutagenesis to replace consensus amino acids of the
PXIXIT-like motif with Ala (AXAXAA) and tested whether
the expression of the Ala-substituted PDE4Ds was regulated
by ionomycin or CsA (Fig. 4B). Immunoblot analysis indicated
that PLNLYR496 and PEACVI666 are functional PXIXIT-like
calcineurin docking motifs in PDE4D (Fig. 4B). Replacement
of PLNLYR496 or PEACVI666 with Ala abrogated the stabili-
zation of PDE4D expression by ionomycin (Fig. 4B). Similarly,
increased degradation of PDE4D in the presence of CsA was
attenuated in Ala-substituted PLNLYR496 or PEACVI666
PDE4D (Fig. 4B). These data indicate that there are two
functional PXIXIT-like calcineurin docking domains in
PDE4D. The location of these functional calcineurin docking
domains in the COOH-terminal conserved catalytic core of
PDE4D implies that all PDE4D isoforms are subject to similar
regulation.
Direct interaction between calcineurin and PDE4D. Next,
we examined whether calcineurin interacts with PDE4D and
whether such interaction requires the two identified
PXIXIT-like motifs (PLNLYR496 and PEACVI666) (Fig.
5A). Coimmunoprecipitation assays showed that endoge-
nous calcineurin interacts with endogenous PDE4D (Fig.
5B). Notably, the calcineurin-PDE4D interaction was atten-
uated by coexpression of a PXIXIT-containing calcineurin
docking inhibitor, dnNFAT (6, 15) (Fig. 5C). Furthermore,
the calcineurin-PDE4D interaction was impaired upon the
replacement of critical residues in the PXIXIT-like motifs
with Ala (ALALAA496 and AEACAA666) in PDE4D (Fig.
5D). Finally, binding assays using purified proteins sup-
ported the concept that calcineurin interacts directly with
PDE4D (data available on request).
CK1 or GSK3 phosphorylates the PDE4D phosphodegron.
Interaction with and stabilization of PDE4D by calcineurin
suggest that the phosphodegron motif (DSGSQVEED623)
might be phosphorylated. We therefore sought protein kinases
that might counterbalance the role of calcineurin in PDE4D
stabilization (Fig. 6). Common Ser/Thr protein kinases that
preferentially phosphorylate target sites encompassing acidic
amino acid residues include CK1, CK2, and GSK3. Phos-
phorylation mediated by GSK3 and/or CK1 can promote
protein degradation (34, 60). Since integration of calcineurin,
GSK3, and CK1 regulates NFAT activation (7, 67), we asked
whether GSK3 and/or CK1 phosphorylate PDE4D.
In vitro protein kinase assays indicated that GSK3 and CK1
phosphorylated the COOH-terminal portion of the PDE4D
catalytic core (Fig. 6A and B), which encompasses the
DSGSQVEED phosphodegron. Replacement of Ser616 and/or
FIG. 5. Direct interaction between calcineurin and PDE4D. (A) Schematic illustration of PDE4D3 and PDE4D3 GST fusion protein.
Functional calcineurin docking motifs (PLNLTR496 and PEACVI666) are indicated. Calcineurin binding-defective PDE4D3 (ALALAA496 and
AEACAA666) is also shown. (B) Binding of endogenous PDE4D and calcineurin was determined by coimmunoprecipitation assays. Endogenous
PDE4D in COS7 cells was immunoprecipitated (IP) using goat polyclonal PDE4D antibody (sc25097), mouse monoclonal calcineurin A antibody
(sc17808), goat polyclonal calcineurin A antibody (sc6124), or goat polyclonal calcineurin B antibody (sc6119). The presence of endogenous
PDE4D in calcineurin immunoprecipitates was analyzed by immunoblot (IB) analysis using rabbit polyclonal PDE4D antibody (sc25814). Mouse
M2 monoclonal antibody was used as a control. (C) PDE4D3 was coexpressed with CnA in COS7 cells. Binding of PDE4D3 and CnA was
determined by coimmunoprecipitation assays. The presence of PDE4D3 in CnA immunoprecipitates and in cell extracts was analyzed by
immunoblot analysis. The effect of the PXIXIT-containing calcineurin docking inhibitor dnNFAT is also shown. (D) Wild-type and calcineurin
binding-defective PDE4D3 were coexpressed in the presence and absence of CnA in COS7 cells. The presence of PDE4D3 in CnA
immunoprecipitates and in cell extracts was analyzed by immunoblotting.
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Ser618 in the phosphodegron with Ala reduced PDE4D phos-
phorylation mediated by GSK3 or CK1 (data available on
request). Replacement of Glu621, Glu622, and Asp623 with Ala
also reduced GSK3- or CK1-mediated PDE4D phosphoryla-
tion (data available on request), indicating that these acidic
amino acid residues are critical for optimal phosphorylation.
These data indicate that CK1 and GSK3 phosphorylate
Ser616 and/or Ser618 at the phosphodegron in PDE4D.
To elucidate the phosphorylation of the phosphodegron of
PDE4D in vivo, we developed phosphospecific antibodies to
detect phospho-Ser616. Immunoblotting analyses demon-
strated phosphorylation of PDE4D3, which increased in inten-
sity upon the coexpression of GSK3 (Fig. 6C). Notably,
GSK3 reduced the expression of PDE4D3, despite increased
phosphorylation of PDE4D3. The replacement of Ser616,618
of PDE4D3 with Ala, however, abrogated the detection of
PDE4D3 by the phosphospecific antibodies (Fig. 6C). In the
presence of MG132 to inhibit proteosomal degradation, phos-
phorylated PDE4D3 accumulated (data available on request).
Together, these data confirm phosphorylation at the phospho-
degron of PDE4D3 in vivo. These data also support the con-
cept that phosphorylation of PDE4D at the phosphodegron is
a prerequisite for subsequent degradation via the proteosome.
CK1 or GSK3 promotes PDE4D degradation via the phos-
phodegron motif. Given that calcineurin reduces PDE4D deg-
radation, we asked whether GSK3 or CK1 mediates the op-
posing effect and potentiates PDE4D degradation (Fig. 7).
Coexpression of either GSK3 or CK1 potentiated the degra-
dation of PDE4D (Fig. 7A). Expression of exogenous Arr-1
and endogenous tubulin, however, was not affected by GSK3
or CK1 coexpression (Fig. 7A). We further ascertained that
endogenous GSK3 or CK1 regulates PDE4D degradation
using the protein kinase inhibitors LiCl and D4476, respec-
tively (Fig. 7B). In the presence of LiCl or D4476, degradation
of PDE4D was reduced (Fig. 7B). Inhibition of CK2 with
DMAT did not affect the degradation of PDE4D (Fig. 7B).
These data demonstrate that the endogenous protein kinase
GSK3 or CK1 phosphorylates PDE4D and promotes its deg-
radation.
Next, we examined whether GSK3 or CK1 regulation of
PDE4D is phosphodegron dependent (Fig. 7C and D). Expres-
sion of GSK3 or CK1 potentiated PDE4D degradation (Fig.
7C and D). The effect of GSK3 or CK1 on PDE4D degrada-
tion, however, was abrogated in phosphodegron-defective
PDE4D (Fig. 7C and D). Conversely, administration of the
inhibitor LiCl or D4476 to block endogenous protein kinase
activity reduced PDE4D degradation (data available on re-
quest). The effect of LiCl or D4476 on PDE4D degradation,
however, was abrogated in phosphodegron-defective PDE4D
(data available on request). These data demonstrate that pro-
tein kinase GSK3 or CK1 phosphorylates PDE4D and pro-
motes its degradation via the phosphodegron.
Evolutionarily conserved regulation of PDE4D degradation
via calcineurin, CK1, and GSK3. Both PDE4 and calcineurin
are highly conserved in evolution from C. elegans to mammals
(18, 21, 41, 53) (Fig. 8A). Indeed, we have identified similar
phosphodegron and calcineurin docking motifs in the C.
elegans PDE4 counterpart (cePDE4) (Fig. 8A). In addition, we
have recently found that ablation of CnA led to sustained
-adrenergic receptor/PKA activation (data available on re-
quest). We found that sustained elevation of cAMP in the
absence of CnA was due in part to impaired cAMP hydrolysis
(data available on request).
Next, we asked whether, in analogy to calcineurin inhibition by
CsA, the expression of PDE4D is altered upon ablation of CnA.
Immunoblot analysis indicated reduced expression of PDE4D
upon the ablation of CnA (Fig. 8B). Expression of PDE4D, as
well as PDE4A and PDE4B, mRNA in CnA/ and
CnA/ cells, however, was indistinguishable (data available
on request). These data indicate that, similar to calcineurin
β
β
FIG. 6. CK1 and GSK3 phosphorylate PDE4D phosphodegron.
(A) Schematic illustration of PDE4D3 and PDE4D3 GST fusion pro-
tein. The location of the DSGSQVEED phosphodegron in PDE4D3
are also shown. Replacements of critical amino acid residues in the
DSGSQVEED phosphodegron of PDE4D3 with Ala are highlighted.
(B) GST recombinant proteins encompassing either the NH2-terminal
or the COOH-terminal portion of the catalytic core of PDE4D3 were
subjected to in vitro protein kinase assays in the presence of recombi-
nant GSK3 or CK1 and [-32P]ATP. Autoradiography and Coomas-
sie blue staining of recombinant PDE4D3 are shown. (C) COS7 cells
transiently transfected with wild-type or Ala616,618 mutant PDE4D3.
The effect of GSK3 was also examined. Phosphorylation of Ser616 of
PDE4D3 was assessed by phospho-PDE4D antibody (Phos-PDE4D)
in immunoblot analysis. Expression of PDE4D3 and tubulin is also
shown.
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inhibition, ablation of CnA reduces PDE4D expression at the
posttranscriptional level.
To further demonstrate the relevance of the calcineurin-
PDE4D signaling cross talk, we used C. elegans as a model
system. Immunoblot analysis demonstrated that the expression
of endogenous cePDE4 was reduced in worms bearing a loss-
of-function mutation in calcineurin [tax-6(p675lf)] (Fig. 8C)
(41). Evolutionarily conserved regulation of PDE4 by cal-
cineurin indicates the importance of this novel signaling cross
talk.
At the molecular level, similar to that of mammalian
PDE4D, degradation of cePDE4 was channeled through the
Cul1-containing SCF E3 ubiquitin ligase complex (data avail-
able on request). Degradation of cePDE4 was reduced by
either expression or activation of calcineurin (data available on
request). Administration of CsA to inhibit calcineurin, how-
ever, potentiated cePDE4 protein degradation (data available
on request). Expression of either CK1 or GSK3 protein ki-
nase also potentiated cePDE4 degradation (Fig. 8D). Notably,
expression of CK1 or GSK3 increased the phosphorylation of
cePDE4, despite the reduced cePDE4 expression in the pres-
ence of these protein kinases (Fig. 8D). Together, these data
demonstrate that regulation of PDE4 protein degradation by
Cul, calcineurin, CK1, and GSK3 is evolutionarily conserved.
DISCUSSION
Calcineurin in cell signaling regulation. In this report, we
uncover a novel calcineurin signaling system (Fig. 9). We find
that calcineurin regulates phosphodependent degradation of
PDE4D, a widely expressed cAMP-degrading PDE that is well
known to underpin key functions of cAMP signaling (18, 33).
We demonstrate that calcineurin binds directly to PDE4D in
order to oppose the novel action of the CK1 and GSK3
protein kinases in phosphorylating a phosphodegron motif in
PDE4D. Such phosphorylation by CK1 and GSK3 allows the
SCF E3 ubiquitin ligase to promote ubiquitin conjugation,
which then targets PDE4D for proteosomal degradation. In-
triguingly, our study of C. elegans indicates that calcineurin
regulation of PDE4D degradation by a phosphodegron is evo-
lutionarily conserved, supporting the importance of this novel
calcineurin-PDE4D signaling system in GPCR/cAMP signal
transduction. Thus, in addition to subcellular compartmental-
ization and phosphorylation-dependent activation (18, 33),
controlling the stability of PDE4D by targeted ubiquitination
involving CK1 and GSK3 phosphorylation and subsequent
recruitment of the SCF E3 ubiquitin ligase complex provides a
novel, evolutionarily conserved control point at which to reg-
ulate cAMP signaling in cells.
Our studies also expand the repertoire of calcineurin func-
tion in regulating protein stability via phosphodegrons. Iden-
tification of substrates targeted for phosphodegron-mediated
degradation has been proven difficult because of complex
phosphorylation events for substrate recognition. These sub-
strates are often phosphorylated at multiple sites and low in
abundance, as they are rapidly degraded once phosphorylated.
Therefore, identification of these substrates becomes a “catch-
22” event, as phosphorylation induces binding to the SCF
adaptors, which facilitate ubiquitin conjugation and promote
degradation. Conversely, interaction with and subsequent de-
phosphorylation by calcineurin will increase the protein stabil-
ity of some phosphodegron-mediated substrates. Future sys-
tematic investigations to identify such substrates will provide
new insights for the pleiotropic effect of calcineurin.
The opposing actions of the phosphatase calcineurin and the
CK1/GSK3 protein kinases on phosphodegron-dependent
FIG. 7. CK1 and GSK3 promote PDE4D degradation. (A) PDE4D3 or Arr-1 was coexpressed with GSK3 or CK1 in COS7 cells. The
expression levels of PDE4D3, Arr-1, GSK3, and CK1 were determined by immunoblot analysis. The expression level of tubulin was used as a
control. (B) PDE4D3 was transiently expressed in COS7 cells. The expression levels of PDE4D3 in the presence and absence of protein kinase
inhibitors for 4 h were determined by immunoblot analysis. The effect of Ion (2 M) is also shown. The protein kinase inhibitors administered
included the GSK3 inhibitor LiCl (20 mM), the CK1 inhibitor D4476 (1 M), and the CK2 inhibitor DMAT (400 nM). (C and D) Wild-type or
phosphodegron-mutated (Ala616, Ala618, Ala616,618, or Ala621,622,623) PDE4D3 was coexpressed with GSK3 (C) or CK1 (D) in COS7 cells. The
expression levels of PDE4D3, GSK3, and CK1 were determined by immunoblot analysis. The expression level of tubulin was used as a control.
4386 ZHU ET AL. MOL. CELL. BIOL.
degradation of PDE4D are analogous to their roles in regu-
lating the nucleocytoplasmic shuttling of NFAT transcription
factors. Coordinated regulation by the phosphatase calcineurin
(and CK1/GSK3 protein kinases) on NFAT-mediated tran-
scription and on PDE4D protein stability would elicit intricate
biological responses. For example, cAMP-dependent protein
kinase (PKA) opposes calcineurin-mediated nuclear NFAT
accumulation (7, 14). Stabilization of PDE4D, and hence
dampening of PKA activation via increasing cAMP hydrolysis,
would facilitate nuclear accumulation of NFAT upon activa-
tion of calcineurin. Induction of NFAT target genes (e.g., T-
cell mitogens) and downregulation of cAMP concentration/
localization in specific cellular compartments by calcineurin
may also contribute to overall T-cell function and proliferation
(1, 2, 56). A similar role for calcineurin in NFAT and PDE4D
regulation may also be found in endocrine secreting cells, such
as adipocytes and pancreatic  cells, where NFAT mediates
the expression of secretory factors (e.g., adiponectin, resistin,
and insulin) (28, 61), while PDE4D regulates exocytic release
via compartmentalized cAMP signaling (58).
Calcineurin in posttransplantation complications. Our find-
ings on calcineurin regulation of the stability of PDE4D have
clinical significance in providing a new perspective on the mo-
lecular pathology of posttransplantation complications elicited
by the widely used calcineurin inhibitor and immunosuppres-
sant CsA. Suppression of immune function by CsA during and
after transplant surgery minimizes the incidence of host-ver-
sus-graft reactions in transplant patients and increases the suc-
cess of organ transplantation. Many of these transplant pa-
tients, however, develop posttransplantation complications
even without a history of such pathologies. Posttransplantation
complications include a broad range of pathologies, including
insulin resistance, hyperlipidemia, hypertension, and nephro-
and neurotoxicity (3, 26, 38, 48). Their etiology, however, re-
mains elusive.
Current models suggest that CsA disrupts the mitochondrial
permeability transition pore function and causes cellular dys-
function in  cells (22). CsA also inhibits calcineurin (54),
which dephosphorylates the transcription factor NFAT (17,
35). Calcineurin-NFAT signaling is critical for pancreatic
-cell growth and adipokine gene transcription (28, 61). Upon
calcineurin inhibition by CsA, dysregulated pancreatic function
and loss of insulin sensitivity can account for the metabolic
complications found in transplant patients.
The effect of sustained elevation of cAMP upon the loss of
calcineurin function in stabilizing PDE4D expression can also
contribute to the adverse pathological complications found in
CsA-treated transplant patients. The diverse functions of
GPCR signal transduction and an array of effectors regulated
by the second messenger cAMP, e.g., cAMP-dependent pro-
tein kinase (PKA) (39, 47), cAMP-gated ion channels (8), and
cAMP-regulated guanine nucleotide exchange factors (Epac)
(31), provide a wide base to account for the pathologies found
in CsA-treated transplant patients. Notably, GPCR antago-
FIG. 8. Evolutionarily conserved regulation of PDE4D degradation via calcineurin, CK1, and GSK3. (A) Schematic illustration of C. elegans
PDE4 (cePDE4). The locations of the potential phosphodegron and calcineurin docking motif are also shown. Sequence alignment and percent
identity with human PDE4D (hPDE4D) are indicated. Bullets indicated conserved amino acid residues. Colons indicated similar amino acid
residues. Asterisks indicated potential phosphorylation sites. (B) Extracts prepared from CnA/ and CnA/ mouse skeletal muscle were
subjected to immunoprecipitation and immunoblot analysis to determine the endogenous expression of PDE4D. The expression level of tubulin
was used as a control. (C) Extracts prepared from N2 wild-type control C. elegans and loss-of-function calcineurin mutant worms [tax-6(p675lf)]
were subjected to immunoblot analysis to determine the endogenous expression of cePDE4. Extracts prepared from PDE4 null worms [pde-
4(ok1290)] were used to show the specificity of the cePDE4 antibody. The expression level of C. elegans tubulin was used as a control. (D) cePDE4
was transiently cotransfected with either CK1 or GSK3 into COS7 cells. Phosphorylation of cePDE4 was determined by immunoprecipitation (IP)
using M2 monoclonal antibody against FLAG-tagged cePDE4 and subsequent immunoblotting (IB) analysis using phospho-Thr polyclonal
antibodies. The expression levels of cePDE4, CK1, GSK3, and tubulin are also shown.
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nists and calcium channel blockers, seemingly unrelated to
calcineurin function, have shown certain success in attenuating
pathological complications elicited by CsA (42, 51, 52, 64). We
propose that metabolic complications found in transplant pa-
tients treated with CsA may be a consequence of not only
pancreatic dysregulation via the insulin pathway but also of
potentiation of the GPCR signaling pathway due to sustained
elevation of cAMP.
Conclusions. In conclusion, we have uncovered a novel, evo-
lutionarily conserved calcineurin signaling system that regu-
lates SCF-mediated ubiquitin conjugation and proteosomal
degradation of PDE4D upon dual phosphorylation by CK1
and GSK3. The calcineurin/ubiquitin/PDE4D signaling sys-
tem impinges on diverse cellular processes by regulating cAMP
responses. This new calcineurin signaling system provides new
insights and points to novel therapeutic targets for a range of
adverse pathological complications elicited by CsA in trans-
plant patients.
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FIG. 9. Model of the phosphatase calcineurin in the -adrenergic signaling pathway via regulation of PDE4D degradation. PDE4D encom-
passes a DSGSQVEED phosphodegron. Phosphorylation at the phosphodegron by the protein kinases GSK3 and CK1 promotes PDE4D
degradation, which is mediated by the SCF E3 ubiquitin (Ub) ligase complex. Ubiquitinated PDE4D was degraded by the proteosome complex.
Conversely, dephosphorylation mediated by the phosphatase calcineurin opposes PDE4D degradation. Thus, phosphorylation-dependent degra-
dation controls the expression level of PDE4D, which in turn regulates the intracellular concentration of the second messenger cAMP upon
activation of the -adrenergic receptor signaling pathway—a key component of the control of diverse physiological responses. The calcineurin/
ubiquitin/PDE4D signaling axis is also evolutionarily conserved in C. elegans, indicating its important role in critical cellular processes to regulate
cAMP duration. We propose that potentiation of the Gs-coupled signaling pathway due to sustained elevation of cAMP, which is a consequence
of reduced PDE4D expression in the absence of calcineurin function, accounts for the metabolic complications (e.g., hyperlipidemia and
hemodynamic dysregulations) found in transplant patients treated with CsA. AC, adenylyl cyclase.
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